Coexisting Anti-NMDA and Anti-GAD65 Antibodies in a Patient with Autoimmune Encephalitis: A Case Report
This case report describes a 56-year-old man with coexisting anti-NMDA and anti-GAD65 antibodies who exhibited a severe, treatment-resistant course of autoimmune encephalitis culminating in death, suggesting that such antibody overlap may predict a poorer prognosis and reduced response to immunotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human brain is a complex organ that usually keeps its own defenses in check, but sometimes the immune system, designed to fight off infections, mistakenly turns against the brain itself. This condition, known as autoimmune encephalitis, causes the body's own antibodies to attack healthy nerve cells, leading to a confusing mix of symptoms that can include seizures, memory loss, personality changes, and movement disorders. While doctors have learned to recognize specific types of these attacks by looking for particular proteins, or antibodies, in the blood and spinal fluid, the picture is not always simple. Sometimes, a patient's immune system produces more than one type of attacking antibody at the same time. This overlap makes the illness harder to identify and potentially more difficult to treat, as the different antibodies may attack the brain in different ways, creating a severe and unpredictable disease course.
A recent case report from a hospital in Turkey brings this complexity into sharp focus by describing the tragic journey of a 56-year-old man who fell ill with a rare combination of these attacks. The man first arrived at a clinic after experiencing brief episodes where he would shout and have his muscles contract, yet he remained able to speak during these moments. Because these events did not look like typical seizures and his brain scans and electrical activity tests appeared normal, doctors initially suspected the episodes were not caused by a physical brain disorder but were instead psychogenic, meaning they stemmed from psychological stress. He was sent home without medication, but four days later, he had another episode of unresponsiveness and was discharged again after a short observation. It was not until twenty days after his first visit that he returned with a full-blown seizure, leading to his admission to the intensive care unit.
Once in the intensive care unit, the man's condition deteriorated rapidly. His family revealed that for about a month, he had been speaking nonsense and behaving strangely, symptoms they had previously dismissed as reactions to family stress. In the hospital, he was lethargic, could not follow commands, and eventually slipped into a coma while suffering from ongoing seizures. A thorough investigation ruled out common infections and showed only mild, non-specific changes in his brain's electrical activity. However, a crucial test of his spinal fluid revealed the true cause: his body was producing two distinct types of antibodies that were attacking his brain. One type targeted a receptor on the surface of nerve cells, while the other targeted a protein inside the cells. This dual attack was confirmed in both his blood and his spinal fluid.
Despite the clear diagnosis, the treatment path was steep and ultimately unsuccessful. Doctors immediately began a powerful course of steroid medication to suppress the immune system, followed by a procedure called plasmapheresis, which filters the blood to remove the harmful antibodies. Although the seizures stopped after the steroid treatment, the man never regained consciousness. He was transferred to another facility to complete the blood-filtering treatment, undergoing five sessions, but his neurological state did not improve. The aggressive immune response had caused severe complications, including a lung infection, and the patient eventually died from septic shock, a life-threatening reaction to that infection.
This case highlights a sobering reality in the study of brain diseases: when a patient carries multiple types of attacking antibodies, the illness may be far more severe and less responsive to standard treatments than when only one type is present. The researchers suggest that the presence of these overlapping antibodies, particularly when one targets the inside of the cell, might signal a disease that progresses quickly and resists the usual therapies. While the initial screening for cancer, which can sometimes trigger these immune attacks, came back negative, the author emphasizes that such patients require long-term monitoring, as the underlying cause can sometimes appear years after the initial illness. This story serves as a stark reminder that when the immune system attacks the brain in multiple ways, the outcome can be devastating, underscoring the urgent need for early recognition and more effective strategies for these complex cases.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.